Current treatments of MS focus on stopping inflammation, but they do not necessarily address the underlying cause. There is significant evidence that Epstein-Barr Virus (EBV) is part of the causal pathway of MS. ATA188 is an anti-EBV neurogenic t-cell therapy being developed by Atara Biotherapeutics, and in this video, I present their fascinating phase I data.